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Abstract 
Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five 
consecutive evidence-based editions were produced, building on the essential medicines 
concept. In 2012, the government changed course to establish a new paradigm, introducing 
adoption of new medicines as the main aim within the recommendation process. The objective 
of the paper is to report efforts to develop Brazil´s national EML, policy changes from 2000 to 
2014, discussing results, challenges, and perspectives. Brazilian EML history and development 
process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 
2014. The Brazilian EML and the WHO Model lists were compared using the Anatomical 
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Therapeutic Chemical system. Overlap between lists was verified and linear trends were 
produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied 
greatly between the selection committees acting before and after 2012. Paradigm-changing 
legislation aiming at linking list compliance to public financing in 2012 produced (i) greater 
importance given to political and administrative stakeholders, (ii) increasing trends in number 
of medicines over the years, (iii) decrease in use of WHO Model List as a reference, (iv) 
substitution of an essential medicines list review and update process by an adoption decision 
output. Other issues remained unchanged. Insufficient efforts for list implementation, such as 
lack of physician education, presented consequences to the health system. Substantial efforts 
were made to produce and update the list from 2000 to 2014. However, continuous and intense 
health litigation disproves process outcome effectiveness.  
Introduction 
Since the late 1970s, the essential medicines concept has guided health systems to adopt 
rational therapeutic choices of medicines in clinical practice. Essential Medicines Lists (EMLs) 
are a necessary strategy to foster cost-effective therapy, rational use of medicines and evidence 
based learning in health systems [1-2]. However, worldwide trends show that essential 
medicines lists are succumbing to new postulates related to rapid uptake of new medicines and 
the WHO Model List is no exception [3]. Protection of individuals and health systems from 
financial burdens are viewed as key to essential medicines characterization and policy in many 
countries [4-7], but is especially challenging in middle and low-income countries [8]. 
In Brazil, the Federal Constitution grants health as a right and regulates, through policies, that 
public institutions take responsibility to ensure that essential health services are provided to all 
Brazilians [9]. Universal access, comprehensive care, equity and public control of the Brazilian 
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Health System are policy landmarks [10]. Federal and regional governments must uphold 
SDWLHQWV¶individual rights, while coping with the financial pressures from the introduction of 
technological innovations [11,12]. Whilst expanding access to new medicines, lack of their 
timely delivery by local governments, market pressures, and less than rational prescribing have 
caused¶ increasing numbers of judicial demands based on the right to new treatment options 
[2,13]. The rising costs of new medicines have increased healthcare expenditures across 
countries [14-16], with growth rates in Brazil matching other countries, in the last 15 years 
[17,18].  
Since 1964, Brazil has a national EML, known as µRename¶, (Relação Nacional de 
Medicamentos Essenciais). With the introduction of the National Medicines Policy [19] in 
1998, Rename became the angular strategy for managing medicines¶ supply and utilization. A 
Rename evidence-based edition was launched in 2000 after 18 years without a coherent list 
review process [20]. Following this, states and municipalities also began drafting Rename-
based lists. In 2001, for the first time, a Brazilian EML Review Committee, Comare was 
established by the Ministry of Health (MoH). Its purpose was to conduct systematic 
assessments of medicines in Rename and to select the most appropriate medicines including 
the necessary changes for treating common and/or neglected diseases [21]. 
In 2012, the National Health Technology Incorporation Committee, Conitec, substituted 
Comare. This novel concept emerged by legislation passed in 2012, eschewing health priorities 
and first and second-line treatments as absolute criteria for an essential medicines list. Firstly, 
µDdoption¶ ± privileging new high-cost medicines - substituted µselection¶ )XUWKHUPRUH
legislation defined as µHVVHQWLDO¶ only those medicines that were financed by the government, 
and not what was deemed essential through a result of the selection process. This inverted logic 
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undermined the essential medicine concept [22-24] and has supported all national EMLs after 
2012. 
The main objective of this paper is to analyze the process of policy change in the development 
of Brazil´s national EML from 2000 to 2014, its main characteristics and results. The Brazilian 
case is relevant for countries embracing constitutional guarantee of universal access to 
medicines. 
 
Methods 
Sources of health policy information 
Rename history and documents about Brazilian EML development produced by the Ministry 
of Health from 2000 to 2014 were collected and analyzed. We searched legislation and registers 
of Comare and Conitec archived materials in the Brazilian National Gazette (Diário Oficial da 
União) and in Ministry of Health (MoH) website were identified. We included proceedings, 
minutes, technical documents and reports, as well as the EMLs produced from 2000 to 2014.  
 
Description and analysis 
Reports, legal ordinances, and minutes from Comare and Conitec were analyzed to obtain 
membership and affiliation, conflict of interest statements, work processes and decision 
responsibilities, procedures for reviews and evidence-based decisions, including inclusion and 
exclusion criteria, and standardized procedures established over time. Results were 
summarized in boxes and figures to describe characteristics and changes made in the process 
over the years. 
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The Anatomical Therapeutic Chemical (ATC) [25] system was used to classify all listed 
medicines in Rename and in the WHO Model List from 2000 to 2014. The number of medicines 
in Rename annual issues were calculated. Medicines were cross-referenced between Rename 
and the WHO Model List. The number of medicines common to Rename and WHO Model 
List, as well as those exclusive to Rename, were established for each edition. Linear trends 
over time were plotted and compared. Tables were organized and graphs were plotted using 
Excel® (Microsoft Corp. Redmond, WA, 2010).  
Results 
 
The 2000 Rename edition and experience of work in medicines selection 1998 to 2000 
During the design of the National Medicines Policy, an ad hoc consultative group covering 
academic and pharmacology competence was convened for review of the Brazilian Essential 
Medicines List (Rename), which had not been updated since 1989. The WHO Model List 
evidence-based criteria for list development were adopted (Box 1) and the 2000 edition of 
Rename was published. 
 
Implementation of an evidence-based EML and improved prescribing policy: the Comare 
strategy 2001 to 2011 
As a result of previous efforts, and keeping to the same selection methodology (Box 1), a 
permanent independent body for the selection of essential medicines was established in 2001 
± Comare [26].  
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Box 1: Drug selection and adoption criteria, and membership requirements in successive 
bodies responsible for the Brazilian National Essential Medicines List from 2000 to 2014 
 
MoH Consultative Body (2000) 
Criteria for drug selection Ad hoc Committee members 
Inclusion criteria: 
x Market approved in the country according to 
current legislation, preferably as a single drug 
x Efficacy, safety, effectiveness, ease of 
administration and cost from pivotal studies 
x Intended for the treatment of prevalent 
conditions (major prevalence in the population 
based on epidemiological data) 
x User-friendly dosage forms 
Exclusion criteria:  
x Recent (less than five-year) introduction into 
the Brazilian market 
x Drug safety and similar effectiveness with 
recommended drugs (to avoid duplication). 
x Academia: 
o National School of Public Health 
(ENSP/Fiocruz); 
o Federal University of Rio Grande do 
Sul (UFRGS); 
x Health services experts: 
o Fernandes Figueira Institute; 
o Evandro Chagas Institute; 
x Non-governmental organizations: 
o Brazilian Society of Medicines 
Surveillance (Sobravime); 
o Consumer Defense Institute (Idec); 
x MoH; 
x Pan-American Health Organization (PAHO-
Br). 
COMARE (2001-2011) 
Criteria for drug selection Requirements of committee members 
Inclusion criteria: 
x Market approved in the country according to 
current legislation, preferably as a single drug 
x Efficacy, safety, effectiveness, ease of 
administration, and cost-effectiveness 
(typically based on drug acquisition costs) 
x Intended for the treatment of prevalent 
conditions (major prevalence in the population 
based on epidemiological data considering 
morbidity and mortality information. i.e. 
cardiovascular diseases, diabetes, lung, prostate 
and breast cancers, and those currently 
considered as priority and neglected diseases 
such as AIDS, malaria, tuberculosis, Chagas´ 
disease, leishmaniasis, and filariasis) 
x User-friendly dosage forms to most age groups 
and adequate for the recommended dosing 
regimen 
Exclusion criteria:  
x Insufficient user experience 
x Recent (less than five-year) introduction into 
the Brazilian market 
x Drug safety and similar effectiveness with 
recommended drugs (to avoid duplication). 
x Recognized scientific background 
x Able to convert information needs into 
answerable questions on drug selection and to 
issue opinions using evidence-based 
knowledge. 
x Able to carry out systematic information 
searches on scientific databases, reviewing 
information (for validity and usefulness) using 
well-known criteria, and valuing obtained 
information. Additionally, being able to judge 
if the findings are applicable to the setting and 
to the assimilative capacity of services 
x Devoid of conflict of interests. However, 
there is a waiver of conflict of interest, which 
includes a formal declaration of either 
exemption or potential conflicts of interest. 
Members are absent from decisions involving 
areas of conflict of interests 
x Pro bono work throughout process. Except for 
reimbursement of recognized travel expenses.  
 
CONITEC (2012 - ...) 
Procedures for evidence-based decisions Committee members and partners 
x Scientific evidence on efficacy, accuracy of 
information, effectiveness and safety of 
medicine, product or health procedure  
x Market authorization or authorization for use 
x The Plenary Committee: members from the 
seven MoH secretariats, the National Health 
Council and the National Physician´s Council, 
the States´ Health Secretaries National 
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x Comparative economic evaluation of benefits 
and costs relative to already incorporated 
technologies (including those for home care. 
outpatient and hospital care)  
Council, the Municipalities´ Health 
Secretaries National Council, the National 
Health Agency and the National Health 
Surveillance Agency. 
x The Conitec Secretariat: officials from the 
Department of Health Technology (DGITS).  
x Partners (institutional): healthcare institutions, 
universities, Health Technology Assessment 
(HTA) networks. 
Sources: [21,28-30]. 
In 2003, Comare was linked to the Department of Pharmaceutical Services (DAF) at the 
Ministry of Health´s Science, Technology and Strategic Health Products Secretariat (SCTIE). 
At that time, another MoH committee, Citec (Comissão de Incorporação de Tecnologias) 
carried out decisions on technology incorporation, which can be defined as process for 
systematic evaluation and consideration what new technologies should be used in healthcare. 
Citec dealt basically with innovations, including medicines. 
Participation of representatives from government, academia, medical and pharmaceutical 
societies, non-government health and patient organizations, and manufacturers legitimized 
Comare recommendations. From 2001 to 2011, Comare membership rules changed at least 
three times, striving to follow WHO guidelines, to increase transparency of decisions and to 
better accommodate different stakeholder perspectives [21, 26]. At first, from 2001 to 2005, 
the 14 Comare members were appointed government officials and recruited among university, 
professional organizations and government bodies. In 2005, the Brazilian Health System (SUS) 
managers became full members and the committee, which expanded to 22 people. In 2008, 
membership from various universities, professional organizations and scientific societies began 
to be renewed every two years. SUS managers from government scientific bodies and from the 
MoH became permanent members [27]. At its peak (2006-2008), Comare comprised 20 to 25 
specialists in medicines selection and in health technology assessment. The greater number of 
members, about two thirds, originated from academia with variations during this period.  
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From 2001, all members were obliged to disclose possible conflict of interest in Comare 
procedures and decisions. After 2006, a conflict of interest form, and all documentation 
necessary to disclose transparency of decisions, including technical opinions and reviews were 
made public. In case there was any involvement or conflict of interest between a member and 
the issue to be discussed or the decision to be made, this member was exempted, from the 
beginning of the process for those occasions a person had a potential conflict of interest. 
From 2001, work involved the use of best evidence, evidence-centered databases and 
standardization through the Brazilian Non-proprietary Name List (DCB) and the WHO 
DDD/ATC classification system. Transparency of decision-making was guaranteed by 
electronically submitted inclusion proposals for evaluation, all made public in the MoH 
website. From 2005, efforts were made to strengthen the drug evaluation process, through 
adherence to internal organizational norms, membership requirements, participation, 
timeframes and deadlines, as well as by greater communication with other stakeholders within 
the MoH. Evidence-based analysis was improved by training and adoption of international 
guidelines and comparative review methods after 2005. 
Requirements for committee membership and drug selection criteria are included in Box 1. 
Comare met monthly, following a planned annual schedule. Requests for modification grew 
with increasing availability of electronic communication. The request form included the 
identification of the applicant and 14 items, among which were the type of modification, 
therapeutic reasons and epidemiological repercussions. Any person or entity could send a 
request to the MoH´s DAF. These were received and forwarded to Comare. The entire process 
took an average of six to eight months, from submission to finalizing the electronic edition.  
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To meet these demands, discussions were systematically carried out within the 24 months 
between each edition of Rename. A protocol was developed to standardize all phases of work. 
The process started with a definition of priorities (through prioritizing criteria and priority 
analysis). This included the establishment of epidemiological relevance, strategic public health 
relevance (for services) and need versus demand assessment for the Brazilian Health System. 
In the second round of analysis, the review questions were drafted and distributed to each of 
the members. Two members researched every individual question, independently, according to 
a pre-established investigational framework. All reviews were made available in print and 
online. Despite in-depth analysis given to priority issues, each new edition was 
comprehensively reviewed for publication. Figure 1 illustrates the process. 
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Figure 1 ± Decision-making procedures adopted by Comare (2005-2011) [21,28] 
 
 
 
Training for evidence-based assessment was carried out every two years, when new members 
were called in. Training involved conforming to a standard opinion scheme, preparing the 
analysis, and drafting opinions with an evidence-based outlook. 
The list and the national formulary were made available on the MoH website and were 
distributed free of charge to health services in states and municipalities. The government 
printed around 50.000 copies for each edition of Rename. An implementation strategy adopted 
by the MoH included financing of rational prescribing courses, based on WHO good 
prescribing pratices, in several Brazilian states and municipalities, involving various national. 
The first course was nation-wide, in 2002 [31].  
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However, there was no widespread dissemination of Rename decisions, and no involvement of 
professional organizations in strategies for promoting list compliance. Apart from guidelines 
on controlled substances and medicines, including antibiotic prescribing and dispensing, and 
the establishment of Therapeutic Guidelines and Clinical Protocols, no norms on general 
communication strategies, such as academic detailing with physicians, were enforced. No 
national programs or nation-wide efforts aimed at enhancing the use of the EML to 
subsequently improve the quality and efficiency of overall prescribing were introduced during 
this period [32].  
 
Procedures for adoption of medicines after advent of the National Health Technology 
Incorporation Committee (Conitec) (2012 -   ) 
Conitec is harbored in a special new department of the Ministry of Health, called Management 
and Incorporation of Health Technologies Department. 
Conitec´s mission is to produce reports to support adoption, exclusion or alteration of health 
technologies in SUS, to establish new clinical protocols or alter existing ones, and to update 
RENAME. The Committee is also responsible for horizon scanning of technology innovations 
and follow-up of technology adoption, including disinvestment [18,33]. 
Conitec membership is dual. The Plenary Committee is composed by members from the seven 
MoH secretariats, the National Health Council and the National Physician´s Council, the 
States´ Health Secretaries National Council, the Municipalities´ Health Secretaries National 
Council, the National Health Agency and the National Health Surveillance Agency. The 
Conitec Secretariat is composed exclusively by officials from the DGITS. The Secretariat 
prepares the technical documentation and invites partners for research and drafting of reports 
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and reviews. The Plenary Committee members make recommendation based on their reports, 
but the final decision, after public consultation or public audience, belongs to the MoH´s 
SCTIE Secretary. 
All members (Plenary and Secretariat) must sign a confidentiality agreement and disclose any 
conflict of interest that may relate to issues discussed by the Committee. 
The Committee´s procedures were defined in the 2012 legislation [29] and stated that all 
analyses for adoption of medicines should be based on efficacy, effectiveness, safety and on 
cost (and cost-effectiveness) impact studies of adopted medicines in the public health system. 
Medicines included in submissions for adoption must also display a valid marketing 
authorization. It further states that all medicines offered by the system must be based on official 
MoH clinical protocols. If such protocols are not yet available, supply is to be made based on 
public health system lists [30]. Conitec, however, drafts a list including all medicines, not only 
first and second-line treatment options. The main query Conitec explores is if a certain product 
should be included or modified or if its indication should be altered. A continuous effort in the 
comprehensive review of the list and the inclusion of therapeutic classes, such as oncology 
medicines, absent from Rename since 2012, has not yet been made, as consequence of policy. 
The idea of health priorities and of medicines for health priorities has also not been clearly 
defined. 
In order to analyze requests that reach the Committee, a number of healthcare institutions and 
universities throughout Brazil have been admitted as partners. Conitec has also stimulated the 
creation of health technology assessment centers located in specialized hospitals and 
universities in Brazil. These partners do not have Committee member status and do not 
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participate in decisions. Box 1 summarizes procedures for decisions, according to legislation 
and Conitec composition. 
The MoH or any government office, health professionals, the pharmaceutical industry, 
academia, patient groups, and other bodies, may ask for adoption of new medicines, exclusion 
or any modification of existing medicines and their place in therapy in the current guidelines. 
According to the norms, Conitec has 180 consecutive days (period can be postponed 90 days 
with due justification by Conitec) to finalize any claim that is brought forward, including public 
consultation and publication of decision in the Brazilian National Gazette [30,33]. Conitec has 
a planned yearly schedule and meets regularly, mostly every month. Until August 2017, 58 
meetings had taken place. Meeting minutes are available online [34].  
Proposals must be submitted to the MoH and comprise a letter, full documentation on the 
submitting party, technical forms (for public health system demands and a different one for 
demands originating outside the system), main document (claim), and corroborating studies 
published in the scientific literature. The main document should include a full description of 
the disease or health condition related to the technology, a technical description of the 
technology, comparisons to other technological options already available in SUS ± which can 
be accomplished through a systematic review of the available evidence or, in absence of this, 
a scientific opinion paper. Finally, an economic assessment in the perspective of SUS, and an 
economic impact analysis must be submitted, followed by related references [34]. Conitec may 
not recommend funding if the data does not support the inclusion of the new technology on 
cost and effectiveness grounds (as seen with insulin glargine, in 2014) [12]. 
Decision-making procedures by Conitec are summarized in Figure 2. 
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Figure 2. Decision-making procedures adopted by Conitec (2012-   ) [29,30] 
 
Main changes between Comare and Conitec procedures are basically four: (i) prioritization is 
now a function of internal (to MoH) and external demand and decisions must be reached in 180 
days (postponed by 90 days in exceptional circumstances); (ii) technical opinions and reviews 
are carried out by ad hoc consultants; (iii) decisions are political-administrative in nature, albeit 
supported by technical opinions and reviews; (iv) Conitec must publish indication-limited 
guidelines on high-cost medicines after 180 days of adoption decision (v) Each Rename 
publication (new list) does not involve comprehensive review.  
 
Drug Substances in Rename Editions 2000 to 2014 
From 2000 to 2014, an increase of approximately 160% in number of medicine dosage forms 
were found both Rename (from 520 to 846) and in the WHO Model List (from 529 to 856), 
while medicines according to ATC varied 132% in Rename (from 33 to 440) and 120% in 
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WHO Model List (from 327 to 392). Notwithstanding the 2006 Rename and 14th WHO Model 
list (2005), which presented a decrease in the number of medicines and medicine dosage forms, 
all other editions of both lists showed a positive increment in each new edition. The 16th edition 
of the WHO Model List showed a 21.7% increase in medicine dosage forms (from 600 to 730) 
and the 2012 edition of Rename a 36.4% increase (from 593 to 809) in the same category.  
Since 2012, Rename does not list all antineoplastic agents, ophthalmic preparations or 
medicines used in medical emergencies. The actual number of unlisted items and their 
description cannot be adequately noted, mainly because a comprehensive list of oncology drugs 
offered by the public health system in Brazil has not been available since the 2010 edition of 
Rename. Procedures that are financed by the Brazilian public health system are listed and 
medicines are mentioned inside procedure description. Each provider is given leeway to choose 
which medicine to give to patients in a specific therapeutic procedure [35]. Access to this data 
is limited to system managers and MoH staff. 
The increase in number of medicines both in Rename and in the WHO Model List, as well as 
the number of coincident and discrepant medicines are shown in Figure 3. There was relative 
stability in the number of common medicines in both lists over time, as indicated by the very 
low coefficient of determination of the linear trend (R2 = 0.03219). From 2000 to 2010 a mild 
slope is observed (R2 = 0.41091), due to the growing number of medicines included only in 
Rename. However, after 2012, a considerably steeper slope, caused by the intense addition of 
medicines to Rename may be observed (R2 = 0.90184). 
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Figure 3. Number of Medicines (ATC) in Rename and WHO Model List, number of medicines 
common to both lists (with linear tendency) and number of medicines exclusive to Rename 
(with linear tendency). Brazilian National Essential Medicines List (Rename) and WHO Model 
List of Essential Medicines, 2000-2014. 
 
The 2008 and 2010 reviews produced complete formulary editions. To provide guidance for 
health professionals regarding the rational use of medicines, 2008 and 2010 formularies 
produced accurate and objective information on indications, contraindications, precautions, 
adverse effects, interactions, and care management, guidance to patients, commercially 
available dosage forms, and pharmaceutical information for the prescribers (physicians, 
dentists and, according to Brazilian law, registered nurses working in primary health care). 
Since 2010, no new formularies have been published, contrary to legislation [36]. 
Discussion 
Since the approval of the National Medicines Policy in Brazil in 1998, there were several efforts 
to build a consistent Essential Medicines policy: setting up committees, involving a wide range 
of members; organizing the review process; introducing and adapting criteria for drug 
selection, and thereby establishing relative independence from financing decisions. However, 
continuity of these efforts was abruptly severed by paradigm-changing legislation that strained 
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the concept of essential medicines and changed the focus to an adoption process that prioritizes 
HTA. From 2012 on, µessential medicines¶ were those financed by the system. Countrywide 
public health relevance was underwritten as a principle, but second in importance. 
This was a clear sign of demand (as the driver adhered to by Conitec) versus need (as an 
unwritten guiding principle adopted by earlier selection efforts). Therefore, the status of being 
µHVVHQWLDO¶ KDV ORVW importance in the Brazilian policy agenda. Even though HTA is rightly 
established as the most important tool for the choice of best technologies, it is a method and 
not a policy pathway. Essential medicines selection has ceded to innovation and adoption as an 
organizing principle for medicines availability within the health system [22,31,37]. 
This fracture in policy rationale continuity may be observed at least in three distinct outcomes. 
Initially, technical, and public health personnel made selection decisions; after Conitec there 
was a shift in selection decision-making with a greater weight given to political and 
administrative stakeholders. A second output may be observed in the increasing trends in 
number of medicines over the years, and the decrease in use of the WHO Model List as a 
reference. Both a study on burden of disease [37] and an MoH report [38], corroborate that a 
greater number of medicines have been listed after 2012 to treat the same number of diseases. 
This situation may be summarized on the third output, which is the overshadowing of an 
essential medicines list review and update process by an adoption decision process. 
In the initial environment (Comare) there were more than sufficient technical conditions to 
carry out an essential medicines selection process. Comare made a careful and thorough 
evidence-based selection process, while a separate body, Citec, made adoption decisions. 
However, other key aspects related to the implementation of the essential medicines concept 
failed to thrive. Prescribing practices did not change over the time period Comare existed [32]. 
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Comare efforts were diminished by the lack of any effective dissemination strategy, nationally, 
regionally or locally. In addition, there was little or no involvement of prescribers in the 
development process and no monitoring of adherence by health authorities [32].  
Conitec was much more efficient in meeting certain challenges, such as, integrating technical 
expertise with political decisions in the same body, effectively publicizing the decision-making 
process and posting it online, as well as the outcomes (HTAs) and inviting public participation 
through online consultations. Comare was criticized for the time needed to revise the list and 
reach decisions. Conitec solved this problem with the help of ad hoc HTA consultants, albeit 
with a possible expense in list balance and consistency, due to focus on new medicines and 
novel uses [30]. Conitec also supported research efforts to help managers implement strategies 
for list implementation, such as a pilot study in academic detailing [39]. However, research has 
not yet been successful in changing prescriber attitudes or practices in the country. 
Unfortunately, academic detailing has not yet been adopted as official federal policy, or as 
practice.  
EMLs have been known to enhance the quality and efficiency of prescribing. Familiarity with 
a limited number of essential medicines, with known outcomes and typically less expensive 
than newly marketed ones, enhances therapy effectiveness and reduces drug-drug interactions 
as well as adverse events [4,7,40-42]. However, it is important that recommendations are 
adhered to in clinical practice to gain maximum patient and health service benefit. In spite of 
multiple demand-side and supply side reforms implemented across the country, there have been 
limited demand-side measures to specifically influence physician prescribing in Brazil, which 
reduces adherence to the EML [13,43]. Prescribers are prone to many influences and competing 
interests [15, 43-45]. Any strategy enhancing adoption of essential medicines must involve 
changes in prescribing culture [4]. ,QVWHDGµKDUG¶UHJXODWLRQWKURXJKOHJLVODWLRQZDVYLHZHG
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as a valued strategy, but in this case, has proven ineffective in counteracting commercial forces 
to influence prescribing [28,29,36]. It is not surprising therefore that there was limited 
knowledge and adherence to the EML [4,7,15, 46-48]. 
Some examples of effective ways to incorporate the EML concept into routine clinical care to 
maximize WKHLU EHQHILW KDYH EHHQ LPSOHPHQWHG 7KH µ:LVH /LVW¶ H[SHULHQFH LQ 6WRFNKROP
Metropolitan Health Care Region, with strict efficacy, safety and cost-effectiveness selection 
criteria and implementation of the list in primary and outpatient hospital care [4] Respected 
pharmacotherapeutic experts jointly working with clinical pharmacologists, pharmacists and 
general practitioners work in over 20 expert groups. They suggest which drugs are selected and 
included in the list [4,49]. What mostly makes this experience successful is the wide 
dissemination and communication strategy, with resulting high points for physician adherence 
[4,49,50]. In Scotland, a mutual list of recommended medicines for primary and hospital care 
has been present for over 20 years [50]. The Scottish model to improve the rational use of 
medicines includes multiple measures to enhance adherence to the recommended list of drugs. 
These include academic detailing, prescribing targets and financial incentives [11,46,47]. 
7KHUHLVDOVRQR³carte blanche´IRUVSHFLDOLVWSK\VLFLDQVZLWKWKHIRUPXODU\DQGLWVJXLGDQFH
applying equally across sectors [50]. Both systems enhance the accountability of prescribers 
through regular feedback on their medicine use and apply multifaceted methods needed to get 
adherence and acceptance of recommendations by prescribers [4,39]. Even though these 
experiences come from small, high-income settings, they might be considered as a beacon for 
low and middle-income countries, because of the relative simplicity and straightforwardness 
of interventions, which integrate selection and implementation. 
Even for the novel conformation of Conitec, the lack of a true essential medicines list, with 
medicines for health priorities compromises the possible positive policy results because of the 
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loss of the essential medicine perspective. An EML is a compass for many other health policies 
and industrial policies, that must be in alignment to produce better health outcomes [19]. 
Reducing the importance of the essential medicines concept has consequences on financing 
and on local production and in a certain way eliminates a crucial axis on which may revolve 
regulation and priority decisions for all policies and for health innovation [37]. Recently an 
example of fast change, not exactly compatible with the traditional EM concept [8, 51], and 
with consequences for health outcomes, was the rapid incorporation of telaprevir and 
boceprevir, new DAAs for Hepatitis C. At the time this was perceived as a correct choice, due 
to existing evidence [52]. However, after very serious adverse effects were identified, these 
medicines were also rapidly disenfranchised ± but with serious health consequences remaining, 
as well as considerable costs for the country and a difficult, if not impossible, delisting, due to 
social pressures [53]. Delisting or moving to second generation DAAs is now taking place 
across countries, including Brazil. The country, faced with growing litigation, has also 
advanced in forging a disinvestment protocol, fuelled by Conitec [18,52,53]. 
During the last fifteen years, commitment to the essential medicines concept diminished in 
Brazil. Municipal and state governments were overwhelmed by growing health litigation 
[13,22], by pressures for the inclusion of innovative medicines in lists [54,55] and by the 
independent action of MoH departments, which promoted their own lists. The central changes 
[28,29,36] in the selection process, which established Conitec and the regulation involving 
medicines financing can be interpreted as a counter measure to decrease litigation, but to little 
avail. Recent rulings by the superior courts have stressed the unacceptable level of litigation in 
the country, and extreme measures to counter demands, since the expenses to cover medicines 
demands have strained most municipal, state and federal budgets [56]. The Judicial system is 
absorbing this fact very slowly, through rulings that are less complacent to demands and more 
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adherent to the recognition and enforcement of SUS protocols, as legitimate references for 
public financing of medicines [57].  
Since 2012, anti-cancer agents are not listed in Rename, except for extremely high-priced 
medicines, which were causing insolvency in public and private hospitals, reason which 
determined adoption by Conitec, as an opportunity for transferring costs to the MoH [55]. 
According to Grossmann & Wild, there is not much knowledge of clinical benefit at time of 
approval for many new cancer medicines [58]. Survival benefit is small, whilst prices are 
substantially higher than existing standards [58,59]. Ever increasing prices of new anti-cancer 
medicines are imposed on governments by pharmaceutical companies, which exploit the 
important morbidity and mortality associated with the disease [58]. This needs to be urgently 
addressed by the MoH else insolvency will grow. 
The new procedures implemented by policy and institutionalized by Conitec were not capable 
of giving transparency to the true availability of antineoplastics in SUS [35,60] preventing 
policy assessment and impeding therapeutic audit. Policy grants providers a free choice of 
treatment options for a given type of cancer, despite elective recommendations for cancer care 
by the MoH [35]. Treatment procedures are registered in a reimbursement database, fed by 
providers. Procedures include medicines, but tracing them is challenging [60] and comparing 
treatments offered by different providers is very difficult. Because the National Cancer Institute 
cannot sole-handedly provide care, it is perceived that giving prescribers and providers a free 
rein is necessary for guaranteeing the offer of services for the population. Despite being tacitly 
regarded as a particular situation GXHWRµVSHFLILFLWLHV¶LQFDncer care [61], the absence of cancer 
medicines in Rename, and the lack of mandatory protocols and therapeutic guidelines is 
contrary to the law [36]. Its contribution to rational use, policy implementation or equity in 
cancer care is at best speculative, and possibly detrimental. 
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Moreover, since 2008 a National Formulary, which is also an important strategy for list 
implementation, has not been issued by the MoH. The existence of an updated list-related 
formulary is invaluable for physician training and rational prescribing [32], but its development 
is time-consuming and intrinsically bound to the selection process. Rapid turnover of medicines 
in the list or addition of new medicines with scant efficacy and/or safety evidence may 
compromise the effort entirely [1].  
Even if admitting that facing obstacles to sustainability represented by rapid innovation and 
adoption is a long and strenuous cause [3,8,51], the discussion must be brought back to the 
core of the health system and to the importance of the drug selection process. The necessary 
structure for rational drug use starts with the list, but needs collaboration of prescribers, 
dispensers, health professional training and comprehensive therapeutic processes, such as 
guidelines and their firm enforcement inside the health system. This is particularly important 
because only a small minority of new medicines are actually innovative, the vast majority being 
similar or presenting only marginal improvements over existing medicines [16]. This structure 
gives feedback to what essential medicines to select, how to do it and how to publicize such a 
list, to enhance physician adherence and, as a result, help improve the future care of patients 
[4,7,39]. 
 
Perspectives on needed changes for the future 
The Brazilian National EML experience has shown that even if substantial investment in an 
essential medicines-based policy is made, the lack of dissemination and of cultural change will 
undermine these efforts. The six reviews of Rename were not determinants in the actual 
adoption or use of the list by prescribers. 
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The change in outlook, from selection to adoption, does not appear to have improved the 
effectiveness of list implementation. Taking decision-making from a technical base and 
transferring it to a political-administrative body does not appear to have changed the results for 
the health system. Litigation, a thermometer for effectiveness of the EML process in Brazil, 
has soared putting extreme pressure on the funding of public healthcare. 
The size of the list has not changed attitudes towards prescribing and, in fact, made matters 
worse by making management of medicines supply more difficult and prescribers less aware 
of changes over time, a dire consequence in a country which has embraced the principles of 
universal access since the late 1980s. 
The possible aggravating circumstance - the 2012 policy change ±, which substituted the EML-
concept-based list for a financing list, has failed to decrease health costs and litigation. Intense 
pharma company pressures (on patients and prescribers) have contributed to litigation and rapid 
adoption of new medicines, despite efficiency of new procedures of health technology 
assessment of new medicines and new efforts in building a disinvestment framework. The 
result may prove a daunting challenge to the sustainability of the Brazilian Health System.  
There might be opportunities for a turnaround in Brazilian policy regarding the rational use of 
medicines. Perhaps health litigation, perceived as a scourge to health system management, may 
prove influential in making managers and prescribers understand that matters must change back 
to EML concepts, to prescriber pharmacotherapeutic education for rational use, and to 
sustainable guidelines for priority diseases, to enhance the sustainability of the health system. 
This remains to be seen. 
Both a sound definition of what an essential health technology is as well as how and when to 
adopt it ± ideally through a comprehensive, participative, technically-centered evidence-based 
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process, complemented by protocols and formularies ± must be complemented with effective 
implementation, so the novel outlook may percolate throughout the health system. Changes in 
prescriber attitudes may be achieved by efforts in training and capacity building, and also by 
consistent, continuous work in academic detailing and follow-up, to support clinical decisions. 
An effective EML process is much more than making political-administrative decisions for 
medicines financing, albeit supported by technical evidence. The EM concept and list 
implementation has to do with making government, regulators and society confidant that the 
truly best health decisions are being made.  
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Box 1: Drug selection and adoption criteria, and membership requirements in successive 
bodies responsible for the Brazilian National Essential Medicines List from 2000 to 2014 
 
MoH Consultative Body (2000) 
Criteria for drug selection Ad hoc Committee members 
Inclusion criteria: 
x Market approved in the country according to 
current legislation, preferably as a single drug 
x Efficacy, safety, effectiveness, ease of 
administration and cost from pivotal studies 
x Intended for the treatment of prevalent 
conditions (major prevalence in the population 
based on epidemiological data) 
x User-friendly dosage forms 
Exclusion criteria:  
x Recent (less than five-year) introduction into 
the Brazilian market 
x Drug safety and similar effectiveness with 
recommended drugs (to avoid duplication). 
x Academia: 
o National School of Public Health 
(ENSP/Fiocruz); 
o Federal University of Rio Grande do 
Sul (UFRGS); 
x Health services experts: 
o Fernandes Figueira Institute; 
o Evandro Chagas Institute; 
x Non-governmental organizations: 
o Brazilian Society of Medicines 
Surveillance (Sobravime); 
o Consumer Defense Institute (Idec); 
x MoH; 
x Pan-American Health Organization (PAHO-
Br). 
COMARE (2001-2011) 
Criteria for drug selection Requirements of committee members 
Inclusion criteria: 
x Market approved in the country according to 
current legislation, preferably as a single drug 
x Efficacy, safety, effectiveness, ease of 
administration, and cost-effectiveness 
(typically based on drug acquisition costs) 
x Intended for the treatment of prevalent 
conditions (major prevalence in the population 
based on epidemiological data considering 
morbidity and mortality information. i.e. 
cardiovascular diseases, diabetes, lung, prostate 
and breast cancers, and those currently 
considered as priority and neglected diseases 
such as AIDS, malaria, tuberculosis, Chagas´ 
disease, leishmaniasis, and filariasis) 
x User-friendly dosage forms to most age groups 
and adequate for the recommended dosing 
regimen 
Exclusion criteria:  
x Insufficient user experience 
x Recent (less than five-year) introduction into 
the Brazilian market 
x Drug safety and similar effectiveness with 
recommended drugs (to avoid duplication). 
x Recognized scientific background 
x Able to convert information needs into 
answerable questions on drug selection and to 
issue opinions using evidence-based 
knowledge. 
x Able to carry out systematic information 
searches on scientific databases, reviewing 
information (for validity and usefulness) using 
well-known criteria, and valuing obtained 
information. Additionally, being able to judge 
if the findings are applicable to the setting and 
to the assimilative capacity of services 
x Devoid of conflict of interests. However, 
there is a waiver of conflict of interest, which 
includes a formal declaration of either 
exemption or potential conflicts of interest. 
Members are absent from decisions involving 
areas of conflict of interests 
x Pro bono work throughout process. Except for 
reimbursement of recognized travel expenses.  
 
CONITEC (2012 - ...) 
Procedures for evidence-based decisions Committee members and partners 
x Scientific evidence on efficacy, accuracy of 
information, effectiveness and safety of 
medicine, product or health procedure  
x Market authorization or authorization for use 
x The Plenary Committee: members from the 
seven MoH secretariats, the National Health 
Council and the National Physician´s Council, 
the States´ Health Secretaries National 
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x Comparative economic evaluation of benefits 
and costs relative to already incorporated 
technologies (including those for home care. 
outpatient and hospital care)  
Council, the Municipalities´ Health 
Secretaries National Council, the National 
Health Agency and the National Health 
Surveillance Agency. 
x The Conitec Secretariat: officials from the 
Department of Health Technology (DGITS).  
x Partners (institutional): healthcare institutions, 
universities, Health Technology Assessment 
(HTA) networks. 
Sources: [21,28-30]. 
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Figure 1 ± Decision-making procedures adopted by Comare (2005-2011) [21,28] 
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Figure 2 ± Decision-making procedures adopted by Conitec (2012-   ) [29,30]
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government, industry, 
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partner
CONITEC
Secretariat
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CONITEC 
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Recommendation
for approval or
rejection
Publication in 
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Gazette
Request for inclusion, alteration
SCTIE 
Secretary decides if
public audience is
needed
Public audience
SCTIE
Secretary
decision
RENAME
revised
PARTNERS
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Figure 3. Number of Medicines (ATC) in Rename and WHO Model List, number of medicines common to both lists (with linear tendency) and 
number of medicines exclusive to Rename (with linear tendency). Brazilian National Essential Medicines List (Rename) and WHO Model List of 
Essential Medicines, 2000-2014. 
 
 
 
